Immunomedics developed Trodelvy, an antibody-drug conjugate used to treat triple-negative breast cancer.
Gilead expects the deal to immediately bolster its revenue growth, and for it to be neutral to accretive to adjusted earnings per share in 2023, as well as"significantly accretive thereafter," Gilead said. Over the years, Gilead has received enormous pressure from investors to put its massive cash pile to work. At the end of 2018, Gilead had $30 billion in cash and short-term equivalents, according to data from YCharts.com.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
Business Business Latest News, Business Business Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Gilead Sciences to buy Immunomedics in over $20 billion dealThe two companies were initially discussing a future partnership before shifting to a takeover negotiation, The Wall Street Journal reported. Macron: No Talent Macron: Racist Macron: a threat to NATO Makron: Colonial governor Macron: Spoiled Macron: Ignorant Macron: France's misfortune Macron: Supporter of putschists and terrorists
Source: trtworld - 🏆 101. / 63 Read more »
Gilead nears deal to buy Immunomedics for more than $20 billion, WSJ reportsGilead Sciences Inc is nearing a deal to buy biopharmaceutical company Immunomedics Inc for more than $20 billion in a deal that would further expand Gilead's portfolio of cancer treatments, the Wall Street Journal reported on Saturday. Isn’t gilead the town/state or what ever in handmaids tale? Under his 👁
Source: Reuters - 🏆 2. / 97 Read more »
Gilead nears deal to buy Immunomedics for more than $20 billion, WSJ reportsGilead Sciences Inc is nearing a deal to buy biopharmaceutical company Immunomedics Inc for more than $20 billion in a deal that would further expand Gilead's portfolio of cancer treatments, the Wall Street Journal reported on Saturday. Under his eye
Source: Reuters - 🏆 2. / 97 Read more »